Novartis decision hurts NexMed shares

Novartis will not submit a new drug application for NexMed's topical experimental treatment for nail fungus, and that decision is hurting NexMed's share prices. The drug developer saw shares drop several times throughout the day yesterday. According to Novartis, late stage clinical trials on the treatment, called NM100060, were the cause of the decision. The topical treatment is aimed at mild to moderate toenail fungus.

In 2005, Novartis took on all regulatory, manufacturing, commercialization and clinical development responsibilities for the treatment in an exclusive, worldwide $4 million licensing deal, which had potential to net NexMed up to $47 million.

NexMed is hoping to recover following a mid-2009 release of the results of a comparator study in Europe, according to the company's president and chief executive officer, Vivian Lu.

- see NexMed's release
- read the story at CNN Money
- find out more at Market Watch

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.